Status:
COMPLETED
Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease
Lead Sponsor:
Eli Lilly and Company
Conditions:
Alzheimer Disease
Eligibility:
All Genders
55+ years
Phase:
PHASE2
PHASE3
Brief Summary
This study will compare atomoxetine to placebo when taken with current standard Alzheimer's Disease medications. The treatment will take approximately 6 months and it is hypothesized atomoxetine will ...
Eligibility Criteria
Inclusion
- Patient presents with Alzheimer's Disease based on clinical history.
- Patient must have a Mini Mental Status Score between 10 and 26.
- Patient must have a reliable caregiver in frequent or daily contact with the patient.
- Patient must be currently treated with and on a stable dose of a standard Alzheimer's drug treatment for at least 3 months.
Exclusion
- Patients who are receiving pharmacologic treatments (other than a cholinesterase inhibitor or memantine) for Alzheimer's Disease.
- Patients who have a history in the past 5 years or any current evidence of major psychiatric illness.
- Patients who have narrow angle glaucoma.
- Patients who are experiencing clinically significant urinary hesitancy or retention as assessed by a physician.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT00191009
Start Date
October 1 2003
End Date
January 1 2006
Last Update
November 6 2007
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Sherman Oaks, California, United States
2
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Rochester, New York, United States
3
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
Wichita Falls, Texas, United States